about
Kasabach-Merritt syndrome: pathogenesis and managementδ-Tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl2-induced hypoxiaThe optimal management of polycythaemia vera.Receptor tyrosine kinase mutations in myeloid neoplasms.Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.Perlecan and tumor angiogenesis.High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis.Angiogenesis in developing follicle and corpus luteum.Clonality and altered behavior of endothelial cells from hemangiomas.Angiogenesis is an independent prognostic factor in malignant mesothelioma.Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degenerationRole of endothelial cell-selective adhesion molecule in hematogeneous metastasis.The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge.Selective inhibition of the human tie-1 promoter with triplex-forming oligonucleotides targeted to Ets binding sitesThalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.Increased microvascular network in bone marrow of HIV-positive haemophilic patients.Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL).A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations.Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.Shark cartilage monograph: a clinical decision support tool.
P2860
Q28212044-CB655904-8D57-4564-9E92-197CE1684A91Q34032720-63DA90BC-D660-4318-B5A3-F72857D4EFDCQ34527669-F5AEC8C6-B337-4996-872F-D07A8D1D7CE8Q34655403-BCBDECDC-0A09-472E-912C-C067509771EBQ35039935-31E24DFF-D0B0-45BC-B719-4955A3CA360BQ35043106-240FA91C-DB1E-4DDB-9E74-0EAB9E71F690Q35562693-CD56EC65-0DEC-4B2C-9FB0-E09E3D0CFEA9Q35609350-ED4DB986-ADE6-49B6-AE38-2C537F2A2779Q35750148-6EDDFB77-B258-4577-AAE2-4258FC2F2C88Q35821992-B3CA0BB7-1005-496E-8A8D-ED2EFDAB275CQ36163041-2998E54C-2499-4CCD-93A0-EA633DB8D749Q36643416-50462D4F-7CB7-4011-AD2F-C33713FDBE0BQ36644266-5BD9F187-B9F8-4145-A70D-E29056615574Q37090271-1662F441-6A83-4ABA-92D7-855E6FD7A02DQ37651091-F2284F78-57E2-4373-AC31-358D74E2D953Q38101684-8208FF13-247F-4C9A-9342-02B951F7472DQ38311555-F574050E-1E8F-4659-B6FF-DEA550C291A9Q43622707-7487FB8E-526F-4CC4-8BEC-CAEC51B9DAFBQ45010584-2753D8CD-F970-4EDB-815C-6DFC3CAF0B47Q46146015-A3FBC64D-A5F7-487D-B20C-3E622C981AD0Q46830786-BBF8C6A3-DFA8-4E34-9F00-1BB3F1FA6DD0Q47645420-83220207-6ADC-4794-8A9E-4166AE9C3B2AQ48727704-9ED546F0-F699-4CE9-B6DD-CD8D91FAEE04Q54415704-108A20DE-E62C-45EB-9145-BD8BFAA60184
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Current status of antiangiogenic factors.
@ast
Current status of antiangiogenic factors.
@en
type
label
Current status of antiangiogenic factors.
@ast
Current status of antiangiogenic factors.
@en
prefLabel
Current status of antiangiogenic factors.
@ast
Current status of antiangiogenic factors.
@en
P2860
P1476
Current status of antiangiogenic factors.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.2000.01864.X
P407
P577
2000-06-01T00:00:00Z